Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · IEX Real-Time Price · USD
0.900
-0.027 (-2.94%)
At close: Jun 28, 2022 4:00 PM
0.925
+0.025 (2.789%)
After-hours:
Jun 28, 2022 7:55 PM EDT
Company Description
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders.
Its pipeline includes AL001, an ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's and other neurodegenerative diseases, and psychiatric disorders; and AL002, a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's.
The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Alzamend Neuro, Inc.
Country | United States |
Founded | 2016 |
IPO Date | Jun 15, 2021 |
Industry | Biotechnology |
Sector | Health Care |
Employees | 3 |
Contact Details
Address:
3802 Spectrum Blvd, Tampa, Florida 33612 United States | |
Phone | 844 722 6333 |
Website | alzamend.com |
Stock Details
Ticker Symbol | ALZN |
Exchange | NASDAQ |
Fiscal Year | May - April |
Reporting Currency | US Dollars |
IPO Price | $5.00 |
CIK Code | 1677077 |
ISIN Number | US02262M3088 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Stephan Jackman | Chief Executive Officer and Director |
Henry C. W. Nisser Esq. | Executive Vice President, General Counsel and Director |
Kenneth S. Cragun CPA | Senior Vice President of Finance |
Milton Charles Ault III | Founder and Chairman Emeritus |
Lien T. Escalona | Chief Financial Officer |
David J. Katzoff | Chief Operating Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 28, 2022 | 8-K | Current report |
Jun 21, 2022 | 4 | Statement of changes in beneficial ownership of securities |
Jun 16, 2022 | 4 | Statement of changes in beneficial ownership of securities |
Jun 15, 2022 | 4 | Statement of changes in beneficial ownership of securities |
Jun 9, 2022 | 4 | Statement of changes in beneficial ownership of securities |
Jun 8, 2022 | 4 | Statement of changes in beneficial ownership of securities |
Jun 6, 2022 | 8-K | Current report |
Jun 3, 2022 | 4 | Statement of changes in beneficial ownership of securities |
May 31, 2022 | 4 | Statement of changes in beneficial ownership of securities |
May 26, 2022 | 4 | Statement of changes in beneficial ownership of securities |